Insight Molecular Diagnostics Inc. IMDX 深 沪
已收盘 08-21 16:00:00 美东时间
4.34
+0.040
+0.93%
华盛通- 最 高4.455
- 今 开4.40
- 成交量 3.87万股
- 最 低 4.31
- 昨 收 4.30
- 总市值 1.42亿
- 52周最高 8.51
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.4034
- 委 比 49.62%
- 总股本 3272.43万
- 历史最高 204.80
- 量 比 0.19
- 振 幅 3.37%
- 历史最低 1.922
- 每 手 1
- 风险率 1.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
08-19 08:37
Insight Molecular Diagnostics To Host Virtual KOL Event On August 17 To Discuss GraftAssure Platform Leveraging Digital PCR Technology For Reliable dd-cfDNA Results In Transplanted Organ Health Monitoring
Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that it will host a virtual key opinion leader (KOL) event on Monday, August 17, 2026 at 11AM ET featuring Max Jacob Liebo, MD (Loyola University Medical Center), who will join Nick Ioannou, MD, MHA (iMDx VP Medical Affairs) ...
08-12 04:17
Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing
Insight Molecular Diagnostics Inc. (iMDx) will host a virtual KOL event on August 17, 2026, featuring Max Jacob Liebo, MD, Nick Ioannou, MD, MHA, and Josh Riggs to discuss the GraftAssure platform, which uses digital PCR technology for reliable dd-cfDNA results in transplant organ monitoring. The event will cover the FDA-reviewed GraftAssureDx test for kidney transplant rejection and its implications for heart transplants. iMDx aims to bring test...
08-11 20:05
CORRECTION: Insight Molecular Q2 Adj. EPS $(0.23) Beats $(0.24) Estimate, Sales $239.000K Miss $437.500K Estimate
Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 23.33 percent increase over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $239.000 thou...
08-11 06:24
iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference
Insight Molecular Diagnostics Inc. (iMDx) will report its second quarter 2026 financial results after market close on August 10, 2026, followed by a live Zoom webinar at 2:00 pm PT / 5:00 pm ET. A registration link for the webinar is provided. An archived replay will be available on the company’s website. Additionally, CEO Josh Riggs and CFO Andrea James will participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on A...
08-04 11:00
Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio
Insight Molecular Diagnostics Inc. (iMDx) announced a favorable new Medicare policy expanding coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care, supporting its GraftAssure family of assays. The policy, issued by MolDX, a CMS program, reinforces reimbursement for dd-cfDNA testing, providing clarity for hospitals, clinicians, and laboratories. It establishes a baseline for long-term surveillance testing, increasing test...
07-16 19:22
IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper
Insight Molecular Diagnostics Inc. (iMDx) announced that its Chief Science Officer, Prof. Dr. Ekkehard Schuetz, has published his 200th scientific article. With an H-index of 58, Schuetz ranks in the top 2.5% of researchers globally and top 2% in laboratory diagnostics. He co-invented the dd-cfDNA technology behind iMDx’s GraftAssure family of assays, which aims to revolutionize transplanted organ rejection monitoring. Schuetz’s work has advanced...
06-29 12:00
iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant
Insight Molecular Diagnostics Inc. (iMDx) and the American Society of Transplant Surgeons (ASTS) have awarded a $100,000 grant to Drs. Kenneth Andreoni and Kenneth Chavin to study the health economics of in-house versus send-out dd-cfDNA testing in kidney transplantation. The research aims to compare costs, clinical impact, and operational efficiency to guide transplant programs in choosing diagnostic testing strategies. The findings will support...
06-22 18:07
iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress
Insight Molecular Diagnostics Inc. (iMDx) will showcase its GraftAssure technology at the American Transplant Congress in Boston, highlighting its potential benefits and utility in transplanted organ rejection monitoring. The company will present favorable third-party head-to-head data, host events to discuss the future of transplant monitoring, and announce a grant to evaluate the economics of in-house testing. GraftAssure aims to provide faster...
06-09 20:05
Insight Molecular Diagnostics shares are trading higher. The company reported its Q1 financial results.
Insight Molecular Diagnostics shares are trading higher. The company reported i...
05-15 00:24
